Softwr

Healthcare · head to head

Epocrates vs Paige

Epocrates logo

Epocrates

Healthcare

Mobile clinical reference and decision support app

From
Free
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Only Epocrates has a free tier, so it costs nothing to try first.
  • Each has a real cost: Epocrates pricing page not publicly accessible; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Epocrates covers Drug Reference, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Epocrates and Paige actually diverge.

Attributes where Epocrates and Paige differ
AttributeEpocratesPaige
Starting priceFreeOn request
Pricing modelfreemiumquote
Free tierYesNo
PlatformsMobileWeb, Cloud, On-premise
Founded2000Unknown

Identical on both: user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Epocrates

  • Drug Reference
  • Interactions
  • Dosing Calculators
  • Disease Information
  • Medical Procedures
  • Patient Education
  • EHR Systems
  • HIPAA

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Epocrates

  • Patient Carenot Paige
  • Medical Recordsnot Paige
  • Practice Managementnot Paige
  • Telehealthnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Epocrates
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Epocrates
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Epocrates
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Epocrates

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Epocrates

  • Pricing page not publicly accessible

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Epocrates

Free
  • FreeFree
    • Drug references
    • Calculators
    • Interactions
  • Premium$99/year
    • Enhanced content
    • Offline access

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Epocrates if

  • You need drug reference.
  • You want to start without paying.
  • You work on Mobile.
  • You also want interactions.
Epocrates review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Epocrates or Paige better?
Neither clearly leads. Epocrates starts at Free and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Epocrates or Paige?
Epocrates has a free tier; the other does not. Paid plans start at Free for Epocrates and On request for Paige.
Does Epocrates or Paige run on more platforms?
Epocrates runs on Mobile. Paige runs on Web, Cloud, On-premise.
Can I use Epocrates for free?
Yes. Epocrates has a free tier, so you can try it without paying. Paige starts at On request.
What is Epocrates best used for?
Epocrates is most often used for patient care, medical records, practice management, telehealth. Of those, patient care and medical records are not what Paige is typically brought in for.
What can Epocrates do that Paige cannot?
Epocrates covers Drug Reference, Interactions, Dosing Calculators, Disease Information. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Epocrates: How much does Epocrates cost?

Epocrates pricing information is not available to public access. Users must authenticate or contact the vendor to view pricing details.

Source
Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Epocrates

More on Paige

Keep looking

Other head to heads